CD44v3 and CD44v6 isoforms on T cells are able to discriminate different disease activity degrees and phenotypes in systemic lupus erythematosus patients

被引:10
|
作者
Novelli, L. [1 ]
Barbati, C. [1 ]
Ceccarelli, F. [1 ]
Perricone, C. [1 ]
Spinelli, F. R. [1 ]
Alessandri, C. [1 ]
Valesini, G. [1 ]
Perricone, R. [2 ]
Conti, F. [1 ]
机构
[1] Sapienza Univ Rome, Lupus Clin, Rheumatol Unit, Dept Internal Med & Med Specialties, Rome, Italy
[2] Univ Roma Tor Vergata, Rheumatol Allergol & Clin Immunol Unit, Dept Med Sistemi, Rome, Italy
关键词
CD44v3/v6; systemic lupus erythematosus; biomarkers; disease activity; arthritis; nephritis; AUTOIMMUNE-DISEASE; EXPRESSION; VARIANT; PATHOGENESIS; ARTHRITIS; TARGET;
D O I
10.1177/0961203319838063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Adhesion molecule CD44 contributes to T cell migration into target organs. A higher expression of CD44v3 and v6 isoforms has been identified on T cells from systemic lupus erythematosus (SLE) patients. The aim of this study was to investigate the expression of CD44v3/v6 on T cells of SLE patients in order to evaluate their correlation with clinical features. Methods Sixteen healthy subjects (HSs) and 33 SLE female patients were enrolled. Fifteen patients were in remission (Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) = 0) and 18 patients had an active disease (SLEDAI-2K >= 4). Experiments were conducted by flow cytometry. Results Expression of CD44v3 on CD4(+) and CD8(+) T cells was higher in active patients compared to HSs (p = 0.0097 and p = 0.0096). CD44v3 on CD8(+) T cells was also higher in active patients compared to patients in remission (p = 0.038). CD44v6 was higher on CD4(+) and CD8(+) T cells from active patients compared to HSs (p = 0.003 and p = 0.0036) and to patients in remission (p = 0.01 and p = 0.02). In active patients the ratio CD44v3/v6 was unbalanced towards isoform v6 on both T cell populations. In a receiver operating characteristic curve analysis, CD44v6 on CD4(+) T cells was the most sensitive and specific one (specificity of 81.8%, sensitivity of 75%). Expression of CD44v6 on CD4(+) and CD8(+) T cells correlated with the SLEDAI-2K (p = 0.03, r = 0.38 and p = 0.02, r = 0.39). CD44v6 and CD44v3 on CD8(+) T cells associated with nephritis and arthritis (p = 0.047 and p = 0.023). Conclusions CD44v3/v6 can be used as biomarkers of disease activity and phenotypes; isoform v6 on CD4(+) T cells can be useful as a diagnostic biomarker.
引用
收藏
页码:621 / 628
页数:8
相关论文
共 50 条
  • [21] 粘附因子CD44S、CD44V3、CD44V6在乳腺癌中的表达及临床意义
    吴小进
    殷咏梅
    临床肿瘤学杂志, 2008, 13 (12) : 1069 - 1073
  • [22] CD44H and CD44V6 expression in different subtypes of Hodgkin lymphoma
    Anwar, F
    Wood, BL
    MODERN PATHOLOGY, 2000, 13 (10) : 1121 - 1127
  • [23] Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints
    Wibulswas, A
    Croft, D
    Pitsillides, AA
    Bacarese-Hamilton, I
    McIntyre, P
    Genot, E
    Kramer, IM
    ARTHRITIS AND RHEUMATISM, 2002, 46 (08): : 2059 - 2064
  • [24] CD44v3和CD44v6在溃疡性结肠炎鉴别诊断中的作用
    王玉芳
    魏兵
    欧阳钦
    中华内科杂志, 2004, (08) : 68 - 69
  • [25] 周围型非小细胞肺癌CT征象、预后与CD44v3、CD44v6表达的相关研究
    章绪辉
    罗良平
    周序珑
    陈金城
    中国医学影像技术, 2009, 25 (07) : 1195 - 1198
  • [26] CD44V3、CD44V6和Ki-67在乳腺癌组织中的表达及意义
    任立群
    齐洁敏
    宫凤春
    山东医药, 2008, (24) : 10 - 11
  • [27] Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules
    Gasbarri, A
    Martegani, MP
    Del Prete, F
    Lucante, T
    Natali, PG
    Bartolazzi, A
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3494 - 3502
  • [28] CD44v6 CAR-T cells for the treatment of AML and MM
    Bondanza, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 41 - 41
  • [29] Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids
    Afify, A
    Pang, L
    Howell, L
    MODERN PATHOLOGY, 2006, 19 : 51A - 52A
  • [30] Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids
    Afify, A
    Pang, L
    Howell, L
    LABORATORY INVESTIGATION, 2006, 86 : 51A - 52A